
May 22, 2023
Creso Pharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to provide the following update on progress through wholly-owned Canadian subsidiary, Mernova Medicinal Inc. (‘Mernova’), which has continued to achieve strong growth in purchase orders in May, as well as an extension of licenses with Health Canada and Canada Revenue Agency.
Highlights:
- $C593,926 (A$662,131i) of new purchase orders (“PO”) secured in May from provincial partners and wholesalers
- Takes total Q2 FY2023 sales to C$1,090,172 (A$1,215,365i) following A$553,957 in POs generated in April 2023 and division’s maiden cashflow positive position in Q1 FY2023
- Ongoing sales highlight Mernova’s leading brand position in Canada, underpinned by a growing product suite and enviable province footprint
- Health Canada License LIC-NQS67FH60D extended for a further five years in accordance with the Cannabis Act and Cannabis Regulations – following stringent review by Health Canada inspectors
- Canada Revenue Agency also extends the Cannabis license under the Excise Act, 2001 for additional five years allowing to maintain security in a form satisfactory to the CRA and in an amount determined by the Regulations Respecting Excise Licenses and Registrations
- Mernova continues to explore the potential to become a Good Manufacturing Practice (GMP) licensed facility and the ability to export products to GMP regulated countries
Strong sales momentum continues in Q2 FY2023:
The Company reports that Mernova has generated C$593,926 (A$662,131i) in new purchase orders in May 2023. New POs are from a range of province partners and wholesalers across Canada and for the Company’s dried flower, pre-roll joint and electronic vaporiser products.
May 2023 sales take total unaudited Q2 FY2023 sales to C$1,090,172 (A$1,215,365i) and follows the A$553,957 in POs generated in April 2023 (refer ASX announcement: 1 May 2023) and the division’s maiden cashflow positive position in Q1 FY2023 (refer ASX announcement: 19 April 2023).
Management is continuing to stringently manage costs associated with Mernova, while focusing on revenue growth. The Company looks forward to providing further sales updates, with these latest POs highlighting Mernova’s growing footprint across Canada and ongoing consumer demand.
Licencing and regulatory updates:
The Company has also continued to advance a number of initiatives to ensure that it continues to operate in line with stringent Health Canada guidelines. Mernova advises that Health Canada has extended license LIC-NQS67FH60D in accordance with the Cannabis Act and Cannabis Regulations for an additional five years, through to February 2028. The license extension follows a thorough Good Production Practices (GPP) inspection by the regulators which deemed Mernova’s facility as fully compliant with the Cannabis Act and Regulations.
Further, the Canada Revenue Agency has also extended Mernova’s cannabis license for an additional five years, through to February 2028. This allows Mernova to maintain security in a form satisfactory to the CRA and in an amount determined by the Regulations Respecting Excise Licenses and Registrations in Canada.
Mernova is continuing to explore the potential to become a Good Manufacturing Practice (GMP) licensed facility and will continue to provide updates as developments materialise.
Management commentary:
CEO and Managing Director, Mr William Lay said: “Mernova continues to deliver strong sales growth via province partners and we have a positive outlook through to the end of Q2 and beyond. We continue to witness pleasing demand for the group’s product range which is now sold through eight Canadian provinces.
“As well, the group’s commitment to acting within regulatory guidelines has been highlighted with the extension of two licenses with Health Canada and Canada Revenue Agency respectively. The Company continues to assess the potential to become a GMP licensed facility and will update shareholders on developments as they materialise.”
Click here for the full ASX Release
This article includes content from Creso Pharma, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
The Conversation (0)
19 September
Cannabis Crossroads: Record US Demand Meets Federal Gridlock
The US cannabis industry is at a turning point. State-level legalization and retail growth continue to accelerate, but federal policy remains stalled, leaving businesses navigating both opportunity and uncertainty. Record consumer demand is driving sales, yet outdated regulations, restrictive... Keep Reading...
22 July
10 Biggest Cannabis Stocks in the US and Canada in 2025
After initial optimism for rescheduling in the US, the cannabis market has faced challenges in 2025. Despite signs of support from US President Donald Trump and members of his administration, regulatory uncertainty persists in the US. Companies are shifting focus to match changes in consumer... Keep Reading...
17 July
Cannabis Market Update: H1 2025 in Review
The first half of 2025 played out differently than many cannabis market participants expected. Heading into the year, there was optimism that rescheduling in the US would reduce or eliminate challenges, but the industry continued to grapple with persistent federal regulatory uncertainty,... Keep Reading...
25 June
Thailand Reverses Course on Cannabis, Moves to Recriminalize Amid Political Fallout
Thailand’s groundbreaking experiment with cannabis decriminalization is rapidly unraveling, with the government formally moving to reclassify the plant as a narcotic and ban recreational sales.The decision has sent shockwaves through an industry once projected to be worth over US$1 billion.The... Keep Reading...
09 May
A State-by-State Guide to Cannabis in Australia
Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will... Keep Reading...
01 May
New Cannabis Consumption Trends, Regulatory Shifts Seen Driving Market in 2025
Understanding trends in the cannabis industry is paramount for investors eyeing a market with steady growth potential, but the landscape is complex as products and regulations continue to evolve. Consumption habits are changing as edibles, vaping and THC beverages gain traction, especially among... Keep Reading...
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00